MedTrace Logo

Does Varenicline Influence Alcohol Consumption in Alcohol Dependent Individuals?

NCT00846859 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 162

Last updated 2011-07-21

No results posted yet for this study

Summary

The aim of the present clinical trial is to investigate whether 14 weeks of treatment with a prescription medication for smoking cessation (European trade name: Champix(R); US trade name: Chantix(R)), can reduce alcohol consumption in alcohol dependent individuals.

Conditions

  • Alcohol Dependence

Interventions

DRUG

varenicline (Champix/Chantix)

14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).

DRUG

placebo for varenicline

14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)

Sponsors & Collaborators

  • Karolinska University Hospital

    collaborator OTHER

  • Malmö University

    collaborator OTHER

  • Sahlgrenska University Hospital

    lead OTHER

Principal Investigators

  • Elin Löf, PhD · Addiction Biology Unit, University of Gothenburg and Beroendekliniken, Sahlgrenska University Hospital, Sweden

  • Bo Söderpalm, MD, PhD · Addiction Biology Unit, University of Gothenburg and Beroendekliniken, Sahlgrenska University Hospital, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2010-08-31
Completion
2011-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00846859 on ClinicalTrials.gov